To our knowledge, only two studies have evaluated circulating OPG and breast cancer survival, with one study measuring circulating postdiagnosis OPG in breast cancer patients (median postdiagnosis follow-up, 8.5 years) [8], as in the current study, and one, in the EPIC cohort, evaluating pre-diagnosis circulating OPG in women who were subsequently diagnosed with breast cancer (median time between blood collection and later breast cancer diagnosis, 4.7 years, median postdiagnosis follow-up, 10.9 years) [9]. This evidence concerns the gene TNFRSF11B and breast carcinoma.